Soulbrain (357780): Where It Stands — 2026-09-23 Deep Dive

2026-09-23 · semiconductor · Soulbrain data page

As of 2026-09-23 (Seoul close). Live numbers on the Soulbrain data page.

Soulbrain (357780 KS): Process Consumable Leader Gains 8.9% on Institutional Buying

Soulbrain surged 8.88% on September 23, 2026, closing at ₩368,000. The advance significantly outpaced the broader market, with the benchmark KOSPI rising 1.04% and the tech-heavy KOSDAQ gaining 0.98%.

Today’s rally builds on an accelerating short-term trend: the stock has posted gains of 10.51% over the past 5 trading days, 11.52% over 20 days, and 7.45% over 60 days. With this move, Soulbrain cleared its 20-day moving average (₩335,775) by 9.60% and widened its cushion over its 60-day moving average (₩312,092) to 17.91%, breaking decisively out of a summer consolidation range.

From a valuation-range standpoint, Soulbrain sits precisely at the midpoint of its 52-week trading band (₩224,500 to ₩501,000), occupying the 51.9% percentile. Despite the recent momentum, Soulbrain has trailed its domestic peer group: the median 20-day return for covered Korean semiconductor stocks stood at +14.43%, compared to Soulbrain’s +11.52%. Today’s move represents a sharp catch-up trade relative to the broader semiconductor complex.

Trading volume was underpinned by institutional demand, with domestic institutional accounts recording net purchases of 23,975 shares. This offset continued foreign selling, as offshore accounts registered a net outflow of 6,877 shares.

Fundamental Drivers: Memory Utilization and Layer Scaling

Soulbrain is a core supplier of mission-critical wet chemicals—most notably high-purity hydrofluoric acid (HF), phosphoric acid ($H_3PO_4$) formulations, and chemical mechanical planarization (CMP) slurries—to Samsung Electronics and SK Hynix. Company-specific drivers supporting the re-rating include:

1. 3D NAND Layer-Count Scaling: Soulbrain holds a dominant market share in high-selectivity phosphoric acid used for selective nitride stripping in 3D NAND fabrication. As memory manufacturers advance architectures beyond 200 and 300 vertical layers, etch times and chemical consumption per wafer rise disproportionately. Market expectations of higher bit-growth targets and fab utilization rates directly translate to consumable chemical volume expansions.
2. Advanced DRAM and Packaging Consumables: Demand for the company’s CMP slurries and advanced cleaning solutions tracks leading-edge DRAM transitions (such as 1b-nm and 1c-nm nodes) and High Bandwidth Memory (HBM) stacking processes, where surface planarity and particle defect control require higher unit volumes of chemical consumables per processed wafer.
3. Operational Leverage over Capex Cycles: Unlike front-end semiconductor equipment makers whose order books fluctuate heavily with capital expenditure cycles, Soulbrain’s revenue is tied primarily to wafer starts and fab operating rates. With utilization normalizing across Tier-1 domestic memory fabs, institutional flows appear to be targeting consumable material suppliers that offer earnings defensiveness combined with operating leverage.

Risks and Caveats

• Customer Concentration: Soulbrain’s revenue remains heavily concentrated among domestic memory majors Samsung Electronics and SK Hynix. Any unilateral adjustment to fab production schedules or aggressive price renegotiations would compress operating margins.
• Foreign Flow Divergence: While institutional investors accumulated 23,975 shares today, foreign investors were net sellers of 6,877 shares, reflecting lingering caution among global accounts regarding non-hardware-direct AI exposure.
• Feedstock Price Volatility: Operating profitability in the chemical division remains exposed to input cost shifts, including market pricing for anhydrous hydrofluoric acid and raw phosphate rock, which cannot always be passed immediately into contract selling prices.

This note was produced by Chip & Cell’s data pipeline with model-assisted analysis. It is not investment advice; verify all figures against primary sources.

Not investment advice. Figures are as of publication and may contain errors — see methodology.